全文获取类型
收费全文 | 1679107篇 |
免费 | 124858篇 |
国内免费 | 23668篇 |
专业分类
耳鼻咽喉 | 22966篇 |
儿科学 | 44914篇 |
妇产科学 | 44960篇 |
基础医学 | 232065篇 |
口腔科学 | 46568篇 |
临床医学 | 156958篇 |
内科学 | 315196篇 |
皮肤病学 | 34233篇 |
神经病学 | 126595篇 |
特种医学 | 65947篇 |
外国民族医学 | 636篇 |
外科学 | 244983篇 |
综合类 | 77511篇 |
现状与发展 | 80篇 |
一般理论 | 496篇 |
预防医学 | 114527篇 |
眼科学 | 41679篇 |
药学 | 135224篇 |
303篇 | |
中国医学 | 18914篇 |
肿瘤学 | 102878篇 |
出版年
2022年 | 14641篇 |
2021年 | 21795篇 |
2020年 | 15880篇 |
2019年 | 17756篇 |
2018年 | 22113篇 |
2017年 | 18605篇 |
2016年 | 19182篇 |
2015年 | 24698篇 |
2014年 | 32533篇 |
2013年 | 39115篇 |
2012年 | 53648篇 |
2011年 | 58552篇 |
2010年 | 35085篇 |
2009年 | 31456篇 |
2008年 | 48946篇 |
2007年 | 52192篇 |
2006年 | 53113篇 |
2005年 | 51970篇 |
2004年 | 45364篇 |
2003年 | 43621篇 |
2002年 | 41824篇 |
2001年 | 73298篇 |
2000年 | 76044篇 |
1999年 | 66037篇 |
1998年 | 20483篇 |
1997年 | 19043篇 |
1996年 | 17253篇 |
1995年 | 16319篇 |
1994年 | 14899篇 |
1992年 | 47556篇 |
1991年 | 45800篇 |
1990年 | 44754篇 |
1989年 | 43463篇 |
1988年 | 40563篇 |
1987年 | 39721篇 |
1986年 | 37872篇 |
1985年 | 35936篇 |
1984年 | 26714篇 |
1983年 | 22644篇 |
1979年 | 25599篇 |
1978年 | 18073篇 |
1977年 | 15688篇 |
1975年 | 16320篇 |
1974年 | 19260篇 |
1973年 | 18829篇 |
1972年 | 18007篇 |
1971年 | 16838篇 |
1970年 | 15934篇 |
1969年 | 15334篇 |
1968年 | 14383篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
82.
83.
84.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
85.
European Archives of Oto-Rhino-Laryngology - Several polymorphisms in a disintegrin and metalloproteinase 33 (ADAM33) have been implicated in susceptibility to allergic rhinitis (AR), but the... 相似文献
86.
87.
88.
我国属胃癌高发国家,且以进展期胃癌为主。以手术和化疗为主的多学科治疗无法有效改善晚期胃癌患者的预后。近年来,免疫检查点抑制剂类药物的疗效在诸多癌症中得到了证实,因此,该类药物在胃癌中的治疗效果也受到了广泛的关注。本文对近年来的相关研究成果进行综述,全面介绍了免疫检查点抑制剂类药物在胃癌治疗中的临床应用情况、联合用药情况以及不良反应。对于其他治疗均失败的晚期胃癌患者,PD-1抑制剂是一个可行的治疗选项,其代表药物派姆单抗是目前唯一被美国食品药品监督管理局批准应用于胃癌治疗的免疫抑制剂类药物,而我国国家食品药品监督管理总局尚未批准任何此类药物应用于胃癌的临床治疗。如何进一步提高治疗的客观缓解率,将会是后续临床和基础研究的一大焦点。 相似文献
89.
Wai Man Mandy Chan Yik Weng Yew Thiam Seng Colin Theng Choon Fong Liew Hazel H Oon 《Singapore medical journal》2020,61(4):194
INTRODUCTIONPsoriasis is a chronic inflammatory condition that affects the skin and joints, and is associated with cardiovascular risk factors, including metabolic syndrome (MetS). We aimed to assess the prevalence of MetS in patients with psoriasis and determine whether there was a correlation between psoriasis severity and MetS in a Singapore population.METHODSThis was a cross-sectional study of patients with psoriasis, aged 18–69 years, who attended a tertiary dermatology referral centre in Singapore from October 2007 to February 2009. Fasting glucose, lipids, blood pressure, Psoriasis Area and Severity Index, and body mass index were measured. MetS was diagnosed in the presence of three or more criteria of the modified National Cholesterol Education Program Adult Treatment Panel III.RESULTSAmong 338 patients with psoriasis, there were 238 (70.4%) men and 100 (29.6%) women, who were Chinese (n = 228; 67.5%), Malay (n = 52; 15.4%) and Indian (n = 58; 17.2%). The prevalence of MetS was 45.1%. MetS was 44% more prevalent in patients older than 50 years (p = 0.02). Malay patients with psoriasis were significantly more likely to have hypertriglyceridaemia, elevated fasting plasma glucose and abdominal obesity. There was no significant correlation between psoriasis severity and risk of MetS.CONCLUSIONThe prevalence of MetS in patients with psoriasis in Singapore was 45.1%, or nearly threefold higher than the Singapore general population. Patients with psoriasis should be screened yearly for MetS and any modifiable cardiovascular risk factors should be actively controlled. 相似文献
90.